Investor Relations

Press Releases

 
Press Releases
  Date Title and Summary View
Aug 4, 2016
- Completes Enrollment of Second Cohort of Patients in RT002 Phase 2 Study for Cervical Dystonia - - Updates 2016 Financial Outlook - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin produc...
Jul 21, 2016
- Conference Call Scheduled for Thursday, August 4, 2016 at 4:30pm ET - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the ...
Jul 14, 2016
- Company plans to initiate global Phase 3 program in the second half of 2016 - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced t...
Jul 5, 2016
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Julian S. Gangolli, President, North America, of GW Pharmaceuticals plc, has been elected to Revance's Boa...
Jun 13, 2016
NEWARK, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today reported results from its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel (RT001) to treat patients with moderate to severe later...
Jun 2, 2016
- Portfolio covers diverse and novel indications, compositions and formulations - - Acquisition expands IP rights into inflammation, pain, dermatologic and neurologic disorders- NEWARK, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in ...
May 31, 2016
NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in two upcoming investor conferences. Revance management is scheduled to present at the Jeff...
May 9, 2016
- Completes Enrollment in REALISE 1 Phase 3 Trial for RT001 Topical for Crow's Feet Lines -- Moves Phase 2 Dose-Escalating Trial for RT002 Injectable for Cervical Dystonia into Second Cohort - NEWARK, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin product...
Apr 25, 2016
NEWARK, Calif., April 25, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the Company will release first quarter 2016 financial results on Monday, May 9, 2016 after the close of market. Revance will...
Apr 4, 2016
NEWARK, Calif., April 4, 2016 - Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, proudly announces that its Chief Operating Officer Abhay Joshi, Ph.D., MBA, was inducted today to the American Institute of Medical and Biological Engineeri...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase
Shareholder Tools